Published in Cancer Res on May 01, 1996
Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol (2008) 2.58
Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J Med Genet (2000) 1.61
Medullary thyroid cancer: monitoring and therapy. Endocrinol Metab Clin North Am (2007) 1.14
A founding locus within the RET proto-oncogene may account for a large proportion of apparently sporadic Hirschsprung disease and a subset of cases of sporadic medullary thyroid carcinoma. Am J Hum Genet (2002) 1.09
Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma. BMC Cancer (2006) 0.93
Deletion of Pten in the mouse enteric nervous system induces ganglioneuromatosis and mimics intestinal pseudoobstruction. J Clin Invest (2009) 0.90
Molecular pathogenesis of MEN2-associated tumors. Fam Cancer (2005) 0.88
Thyroid cancer: current molecular perspectives. J Oncol (2010) 0.87
Mixed medullary and follicular carcinoma of the thyroid. On the search for its histogenesis. Am J Pathol (1999) 0.85
Advanced medullary thyroid cancer: pathophysiology and management. Cancer Manag Res (2013) 0.83
Searching for non-RET molecular alterations in medullary thyroid carcinoma: expression analysis by mRNA differential display. World J Surg (2005) 0.83
Molecular basis of medullary thyroid carcinoma: the role of RET polymorphisms. Int J Mol Sci (2011) 0.83
Mechanisms of inherited cancer susceptibility. J Zhejiang Univ Sci B (2008) 0.80
Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma. J Clin Endocrinol Metab (2017) 0.75
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09
Degenerate oligonucleotide-primed PCR: general amplification of target DNA by a single degenerate primer. Genomics (1992) 9.06
Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab (2001) 6.12
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature (1993) 5.81
Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet (1995) 4.86
Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer (1997) 4.47
Involvement of Brca2 in DNA repair. Mol Cell (1998) 4.41
Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet (1997) 4.16
An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. Am J Hum Genet (1995) 3.81
Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med (1998) 3.60
Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet (1996) 3.53
Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol (2001) 3.35
A clonal marker induced by mutation in mouse intestinal epithelium. Nature (1988) 3.35
Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature (1994) 3.33
Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet (1992) 3.13
Cytogenetic analysis by chromosome painting using DOP-PCR amplified flow-sorted chromosomes. Genes Chromosomes Cancer (1992) 3.03
Development of the pattern of cell renewal in the crypt-villus unit of chimaeric mouse small intestine. Development (1988) 2.97
Transdermal nicotine for active ulcerative colitis. N Engl J Med (1994) 2.90
Mutations truncating the EP300 acetylase in human cancers. Nat Genet (2000) 2.84
Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol (1999) 2.79
An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am J Hum Genet (1993) 2.79
Risk models for familial ovarian and breast cancer. Genet Epidemiol (2000) 2.75
DNA "fingerprints" and segregation analysis of multiple markers in human pedigrees. Am J Hum Genet (1986) 2.55
Familial breast cancer. BMJ (1994) 2.54
Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet (1997) 2.53
DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet (2001) 2.50
Fluorescence, reflectance, and light-scattering spectroscopy for evaluating dysplasia in patients with Barrett's esophagus. Gastroenterology (2001) 2.46
Instability of short tandem repeats (microsatellites) in human cancers. Nat Genet (1994) 2.45
A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev (1999) 2.39
Familial gastric cancer: overview and guidelines for management. J Med Genet (1999) 2.38
Derivation of mouse intestinal crypts from single progenitor cells. Nature (1985) 2.31
DNA replication licensing and human cell proliferation. J Cell Sci (2001) 2.30
Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis. Gut (1994) 2.28
Deletion of genes on chromosome 1 in endocrine neoplasia. Nature (1987) 2.27
Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Res (1998) 2.20
Non-hepatic hyperammonaemia: an important, potentially reversible cause of encephalopathy. Postgrad Med J (2001) 2.14
Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet (1994) 2.14
Identification of 1,25-dihydroxyvitamin D3 receptors and activities in muscle. J Biol Chem (1985) 2.07
Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet (1994) 2.04
Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease. Hum Mutat (1997) 2.04
The extent of linkage disequilibrium in four populations with distinct demographic histories. Am J Hum Genet (2000) 2.03
The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumours. Oncogene (1989) 2.02
Cell migration pathway in the intestinal epithelium: an in situ marker system using mouse aggregation chimeras. Cell (1985) 2.02
Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene (1998) 1.97
A polymorphic stop codon in BRCA2. Nat Genet (1996) 1.95
Stem-cell organization in mouse small intestine. Proc Biol Sci (1990) 1.93
Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II. JAMA (1995) 1.83
A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat Genet (2000) 1.80
Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet (1996) 1.79
Detection of RET proto-oncogene codon 634 mutations using mass spectrometry. J Mol Med (Berl) (1997) 1.77
Overexpression of cyclin D1 in epithelial ovarian cancers. Gynecol Oncol (1997) 1.73
Rapid detection of regionally clustered germ-line BRCA1 mutations by multiplex heteroduplex analysis. UKCCCR Familial Ovarian Cancer Study Group. Am J Hum Genet (1996) 1.72
Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut (1994) 1.72
Genetic mapping of DNA segments relative to the locus for the fragile-X syndrome at Xq27.3. Am J Hum Genet (1985) 1.71
A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol (1998) 1.70
The arrangement of nucleosomes in nucleoprotein complexes from polyoma virus and SV40. Cell (1977) 1.69
Presymptomatic screening for multiple endocrine neoplasia type 2A with linked DNA markers. The MEN 2A International Collaborative Group. Lancet (1991) 1.68
Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease. Hum Mol Genet (1995) 1.68
Paternal origin of new mutations in von Recklinghausen neurofibromatosis. Nature (1990) 1.64
The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res (2000) 1.62
Frequently occurring germ-line mutations of the BRCA1 gene in ovarian cancer families from Russia. Am J Hum Genet (1997) 1.62
Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J Med Genet (2000) 1.61
Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet (1998) 1.61
Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. Hum Mol Genet (1997) 1.55
Nitric oxide mediates a therapeutic effect of nicotine in ulcerative colitis. Aliment Pharmacol Ther (2000) 1.55
An improved urine collection pad method: a randomised clinical trial. Arch Dis Child (2004) 1.55
Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma. Br J Cancer (1999) 1.54
Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, Brca2. Mol Cell (1999) 1.53
Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res (1999) 1.51
Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. Hum Mol Genet (1994) 1.51
Regional localization of 18 human X-linked DNA sequences. Cytogenet Cell Genet (1986) 1.48
Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. UK MRI Breast Screening Study Advisory Group. Magn Reson Imaging (2000) 1.47
Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer. Cancer Res (1996) 1.47
A low proportion of BRCA2 mutations in Finnish breast cancer families. Am J Hum Genet (1997) 1.46
The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. Am J Hum Genet (1999) 1.45
Inhibition of endogenous tissue alkaline phosphatase with the use of alkaline phosphatase conjugates in immunohistochemistry. J Histochem Cytochem (1981) 1.44
Response to methimazole in Graves' disease. The European Multicenter Study Group. Clin Endocrinol (Oxf) (1995) 1.44
Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med (1997) 1.44
Clinical usefulness of a new chemiluminescent two-site immunoassay for human calcitonin. Exp Clin Endocrinol Diabetes (1998) 1.40
Thymic lymphomas in mice with a truncating mutation in Brca2. Cancer Res (1998) 1.36
High allele loss rates at 17q12-q21 in breast and ovarian tumors from BRCAl-linked families. The Breast Cancer Linkage Consortium. Genes Chromosomes Cancer (1995) 1.34
A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. Nat Genet (1992) 1.34
Cowden syndrome and Lhermitte-Duclos disease in a family: a single genetic syndrome with pleiotropy? J Med Genet (1994) 1.33
Phophorylation of polyoma and SV40 virus proteins. J Gen Virol (1977) 1.32
Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. J Clin Endocrinol Metab (1997) 1.31
A study of complaints and their relation to vertebral destruction in patients with osteoporosis. Bone Miner (1990) 1.30
Hereditary ovarian cancer. Heterogeneity in age at diagnosis. Cancer (1991) 1.29
Loss of NF1 alleles in phaeochromocytomas from patients with type I neurofibromatosis. Genes Chromosomes Cancer (1992) 1.29